vs
Side-by-side financial comparison of Howard Hughes Holdings Inc. (HHH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Howard Hughes Holdings Inc. is the larger business by last-quarter revenue ($235.9M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). Howard Hughes Holdings Inc. runs the higher net margin — 3.4% vs 1.6%, a 1.8% gap on every dollar of revenue. On growth, Howard Hughes Holdings Inc. posted the faster year-over-year revenue change (18.4% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -13.8%).
Howard Hughes Holdings Inc., formerly the Howard Hughes Corporation, is a real estate development and management company based in The Woodlands, Texas. It was formed in 2010 as a spin-off from General Growth Properties (GGP). Most of its holdings are focused on several master-planned communities. It took its name from the original Howard Hughes Corporation, which had developed the planned community of Summerlin, Nevada, and later became a subsidiary of GGP.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HHH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $235.9M | $177.4M |
| Net Profit | $8.1M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 121.6% | 3.9% |
| Net Margin | 3.4% | 1.6% |
| Revenue YoY | 18.4% | 5.0% |
| Net Profit YoY | -25.6% | — |
| EPS (diluted) | $0.14 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $235.9M | $177.4M | ||
| Q4 25 | $624.4M | $196.9M | ||
| Q3 25 | $390.2M | $179.5M | ||
| Q2 25 | $260.9M | $181.1M | ||
| Q1 25 | $199.3M | $168.9M | ||
| Q4 24 | $935.0M | $187.3M | ||
| Q3 24 | $327.1M | $168.6M | ||
| Q2 24 | $317.4M | $178.0M |
| Q1 26 | $8.1M | $2.9M | ||
| Q4 25 | $6.0M | — | ||
| Q3 25 | $119.5M | $5.4M | ||
| Q2 25 | $-12.1M | $-4.8M | ||
| Q1 25 | $10.5M | $4.8M | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $72.8M | $-143.5M | ||
| Q2 24 | $21.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 121.6% | 3.9% | ||
| Q4 25 | 4.2% | 1.2% | ||
| Q3 25 | 48.6% | 3.5% | ||
| Q2 25 | 26.0% | 4.7% | ||
| Q1 25 | 24.0% | 1.2% | ||
| Q4 24 | 33.5% | 13.2% | ||
| Q3 24 | 60.6% | -82.8% | ||
| Q2 24 | 20.4% | 15.9% |
| Q1 26 | 3.4% | 1.6% | ||
| Q4 25 | 1.0% | — | ||
| Q3 25 | 30.6% | 3.0% | ||
| Q2 25 | -4.7% | -2.7% | ||
| Q1 25 | 5.3% | 2.8% | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 22.2% | -85.1% | ||
| Q2 24 | 6.6% | 10.6% |
| Q1 26 | $0.14 | $0.07 | ||
| Q4 25 | $0.20 | $0.05 | ||
| Q3 25 | $2.02 | $0.12 | ||
| Q2 25 | $-0.22 | $-0.11 | ||
| Q1 25 | $0.21 | $0.10 | ||
| Q4 24 | $3.14 | $0.38 | ||
| Q3 24 | $1.46 | $-3.11 | ||
| Q2 24 | $0.42 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.8B | $653.9M |
| Total Assets | $11.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | $144.3M | ||
| Q4 25 | $1.5B | $238.4M | ||
| Q3 25 | $1.5B | $246.3M | ||
| Q2 25 | $1.4B | $445.9M | ||
| Q1 25 | $493.7M | $493.6M | ||
| Q4 24 | $596.1M | $484.6M | ||
| Q3 24 | $400.7M | $453.8M | ||
| Q2 24 | $436.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $5.1B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $5.1B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.8B | $653.9M | ||
| Q4 25 | $3.8B | $693.1M | ||
| Q3 25 | $3.8B | $727.2M | ||
| Q2 25 | $3.6B | $757.8M | ||
| Q1 25 | $2.8B | $798.5M | ||
| Q4 24 | $2.8B | $778.3M | ||
| Q3 24 | $2.6B | $749.6M | ||
| Q2 24 | $3.0B | $879.3M |
| Q1 26 | $11.2B | $1.2B | ||
| Q4 25 | $10.6B | $1.3B | ||
| Q3 25 | $10.7B | $1.3B | ||
| Q2 25 | $10.3B | $1.5B | ||
| Q1 25 | $9.3B | $1.6B | ||
| Q4 24 | $9.2B | $1.6B | ||
| Q3 24 | $9.4B | $1.5B | ||
| Q2 24 | $9.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.85× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HHH
| Rental revenue | $113.5M | 48% |
| Master Planned Communities land sales | $99.6M | 42% |
| Other revenues | $11.0M | 5% |
| Builder price participation | $8.7M | 4% |
| Condominium rights and unit sales | $3.1M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
